Indications for: DIPENTUM
Maintenance of remission in ulcerative colitis in patients intolerant of sulfasalazine.
500mg twice a day with meals.
Sulfasalazine allergy. Discontinue if acute intolerance syndrome is suspected. Discontinue at the 1st signs/symptoms of severe cutaneous adverse reactions. Conditions predisposing to myocarditis or pericarditis. Atopic dermatitis or eczema: may have more severe photosensitivity reactions. Nephrolithiasis. Ensure adequate hydration. Renal or hepatic impairment. History of renal disease. Assess renal function prior to and periodically during therapy. Discontinue if renal function deteriorates while on therapy. Elderly: monitor CBCs, platelets. Pregnancy. Nursing mothers: not recommended.
Increased toxicity with nephrotoxic drugs (eg, NSAIDs). Increased risk for blood disorders, bone marrow failure, and associated complications with azathioprine or 6-mercaptopurine and/or other drugs known to cause myelotoxicity; monitor CBCs, platelets if concomitant use is unavoidable. May cause elevated test results when measuring urinary normetanephrine; consider alternative assay. Increased risk of bleeding (eg, hematomas) following neuraxial anesthesia with low molecular weight heparins or heparinoids. Increased prothrombin time with warfarin; monitor and adjust dose. Increased risk of Reye’s syndrome with varicella vaccine; avoid for 6 weeks after varicella vaccine.
Diarrhea, abdominal pain, rash, pruritus; acute intolerance syndrome (cramping, bloody diarrhea, fever, headache, rash), renal impairment, hypersensitivity reactions, severe cutaneous adverse reactions (eg, SJS, TEN, DRESS, AGEP).
Renal. Half-life: ~0.9 hour.
Generic Drug Availability: